Sanofi India · NSE: SANOFI · BSE: 500674
Q4 FY21 results · Jan–Mar 2021
Sanofi India reported revenue from operations of ₹725.10 crore (down 7.6% from Q4 FY20) and net profit of ₹145.90 crore (up 70.8% from Q4 FY20) for Q4 FY21 (Jan–Mar 2021), on a standalone basis.
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 725.10 | 784.50 | −7.6% | 720.30 | +0.7% |
| Other income | 26.30 | 29.50 | −10.8% | 16.20 | +62.3% |
| Total income | 751.40 | 814.00 | −7.7% | 736.50 | +2.0% |
| Profit before tax | 194.90 | 134.60 | +44.8% | 170.20 | +14.5% |
| Net profit for the period | 145.90 | 85.40 | +70.8% | 123.00 | +18.6% |
| EPS, basic (₹) | 63.35 | 37.08 | +70.8% | 53.41 | +18.6% |
| Net margin (%) | 20.1 | 10.9 | 17.1 |
Standalone
- Filed with BSE
- 28 Apr 2021, 11:24 IST
- Board meeting
- 27 Apr 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE